A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor

In brief

This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .

Key facts

Study ID

NCT05142423

Run by

Akeso

People needed

198

Starts

2021-11-03

Expected to finish

2027-04-01

Last updated by the study team

2025-03-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written and signed informed consent.
• Age ≥ 18 years and ≤ 75 years.
• ECOG Performance Status of 0 or 1.
• Estimated life expectancy of ≥3 months.
• Histologically or cytologically documented, locally advanced or metastatic solid tumours (NSCLC, mCRC, HCC, GEJ, etc. ), for which standard therapy does not exist or has proven ineffective or intolerable.
• At least one radiographically measurable lesion per RECIST 1.1.
• Tumor biopsy (during advanced stage) available.
• Adequate organ function.
• Female participants of childbearing potential and male partners with female partners of childbearing potential must agree to use effective barrier methods of contraception during the study and for 120 days after last dose of study drug.

You may not qualify if…

• Other documented active malignancies other than for this trial within 3 years.
• Participation in other clincial trials simultaneously.
• Use of systemic anti-tumor treatments with 4 weeks, non-specific immunomodulating agents within 2 weeks.
• Prior exposure to other T cell coregulatory proteins except for PD-1/PD-L1 inhibitors (apart from cohort B, i.e. treatment naive HCC patients).
• Current use corticosteroids/immunosuppressive agents, permanently discontinuation of study drug, or having any unresolved irAEs (≥grade 2) from prior PD-1/PD-L1 inhibitors treatment.
• Central nervous system (CNS) metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease.
• Uncontrolled pleural/pericardial or peritoneal effusion.
• History of hemorrhagic event need blood transfusion, invasive approaches to intervene, or hospitalization within 3 months, or having high risks of bleeding.
• Any thromboembolic event, non-gastrointestinal fistula or female genital tract fistula within 6 months.
• Uncontrolled gastrointestinal diseases.
• Use of NSAIDs and anticoagulant agents within 7 days.
• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks.
• Severe or uncontrolled hypertension and cardiovascular/cerebrovascular diseases.
• Uncontrolled comorbidities need corticosteroids using.
• Active or prior autoimmune disease or history of immunodeficiency.
• History of interstitial lung disease.
• Known history of active tuberculosis (TB).
• Evidence of active infections including hepatitis B and C.
• Use of anti-infectious agents within 2 weeks.
• History of human immunodeficiency virus (HIV) infections.
• Active syphilis infections.
• Any unresolved toxicities (≥grade 2) from previous anti-cancer therapies.
• Mental illness, drug abuse, or alcohol dependence that may affect compliance with the test requirements.

Where it is running

• First affliated hospital of Zhejiang University — Hangzhou, Zhejiang, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.